J Korean Neuropsychiatr Assoc.  2019 Feb;58(1):18-28. 10.4306/jknpa.2019.58.1.18.

Metabolic Side Effects of Antipsychotic Medication: An Overview

Affiliations
  • 1Department of Psychiatry, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. js_lee@amc.seoul.kr

Abstract

Metabolic syndrome (MetS) is a collection of abnormal clinical and metabolic findings that are predictive of cardiovascular disease. The prevalence (approximately 30-40%) of MetS in patients with schizophrenia is higher than that in the general population, which is one of the reasons why patients with schizophrenia have a reduced life expectancy of 10 to 20 years compared to the general population. Many factors, including low exercise, smoking, unhealthy food, decreased medical service utilization, and treatments with antipsychotics (esp. olanzapine and clozapine), affect the development of MetS in schizophrenia patients. MetS in patients with schizophrenia may begin prior to antipsychotics and occur more often with the treatment of antipsychotics. Therefore, patients with schizophrenia, who are taking antipsychotics, should receive regular monitoring and adequate treatment of MetS.

Keyword

Antipsychotics; Metabolic syndrome; Schizophrenia

MeSH Terms

Antipsychotic Agents
Cardiovascular Diseases
Humans
Life Expectancy
Prevalence
Schizophrenia
Smoke
Smoking
Antipsychotic Agents
Smoke

Figure

  • Fig. 1 Change of metabolic syndrome after 3 years of treatments with antipsychotics. FGA : first generation antipsychotics, SGA : second generation antipsychotics.


Reference

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988; 37:1595–1607.
Article
2. Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol. 2014; 10:425–448.
Article
3. Ringen PA, Engh JA, Birkenaes AB, Dieset I, Andreassen OA. Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions. Front Psychiatry. 2014; 5:137.
Article
4. Laursen TM. Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr Res. 2011; 131:101–104.
Article
5. Laursen TM, Wahlbeck K, Hällgren J, Westman J, Ösby U, Alinaghizadeh H, et al. Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries. PLoS One. 2013; 8:e67133.
Article
6. Capasso RM, Lineberry TW, Bostwick JM, Decker PA, St Sauver J. Mortality in schizophrenia and schizoaffective disorder: an Olmsted County, Minnesota cohort: 1950-2005. Schizophr Res. 2008; 98:287–294.
Article
7. Foley DL, Morley KI. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry. 2011; 68:609–616.
Article
8. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol. 2006; 47:1093–1100.
Article
9. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112:2735–2752.
10. Banerji MA, Lebowitz J, Chaiken RL, Gordon D, Kral JG, Lebovitz HE. Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects. Am J Physiol. 1997; 273:E425–E432.
Article
11. Reaven G. Syndrome X: 10 years after. Drugs. 1999; 58:Suppl 1. 19–20. discussion 75-82.
12. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011; 8:114–126.
Article
13. Mitchell AJ, Vancampfort D, Sweers K, Van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis. Schizophr Bull. 2013; 39:306–318.
Article
14. Hasnain M, Fredrickson SK, Vieweg WV, Pandurangi AK. Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr Diab Rep. 2010; 10:209–216.
Article
15. De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, et al. Physical illness in patients with severe mental disorders I Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011; 10:52–77.
Article
16. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002; 287:356–359.
Article
17. Ministry of Health & Welfare. Prevalence of metabolic syndrome in adult. Seoul: Ministry of Health & Welfare;2017.
18. De Hert M, Schreurs V, Vancampfort D, Van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009; 8:15–22.
Article
19. De Hert MA, Van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 2006; 83:87–93.
Article
20. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005; 80:19–32.
Article
21. Lee NY, Kim SH, Jung DC, Kim EY, Yu HY, Sung KH, et al. The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 35:1273–1278.
Article
22. Lee JS, Kwon JS, Kim D, Kim SW, Kim JJ, Kim JH, et al. Prevalence of metabolic syndrome in patients with schizophrenia in Korea: a multicenter nationwide cross-sectional study. Psychiatry Investig. 2017; 14:44–50.
Article
23. Vancampfort D, Wampers M, Mitchell AJ, Correll CU, De Herdt A, Probst M, et al. A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry. 2013; 12:240–250.
Article
24. De Hert M, Van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health. 2006; 2:14.
25. Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand. 2009; 119:4–14.
Article
26. Bhargava A. A longitudinal analysis of the risk factors for diabetes and coronary heart disease in the Framingham Offspring Study. Popul Health Metr. 2003; 1:3.
Article
27. Arango C, Bobes J, Aranda P, Carmena R, Garcia-Garcia M, Rejas J. CLAMORS Study Collaborative Group. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study. Schizophr Res. 2008; 104:1–12.
Article
28. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry. 1997; 171:502–508.
29. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry. 2000; 177:212–217.
Article
30. Osby U, Correia N, Brandt L, Ekbom A, Sparén P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res. 2000; 45:21–28.
Article
31. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001; 24:683–689.
Article
32. Lyketsos CG, Dunn G, Kaminsky MJ, Breakey WR. Medical comorbidity in psychiatric inpatients: relation to clinical outcomes and hospital length of stay. Psychosomatics. 2002; 43:24–30.
Article
33. Dixon L, Postrado L, Delahanty J, Fischer PJ, Lehman A. The association of medical comorbidity in schizophrenia with poor physical and mental health. J Nerv Ment Dis. 1999; 187:496–502.
Article
34. Robinson DG, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, Lieberman JA. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res. 2002; 57:209–219.
Article
35. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2004; 66:51–57.
Article
36. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007; 64:1123–1131.
37. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005; 150:1115–1121.
Article
38. Druss BG, Zhao L, Von Esenwein S, Morrato EH, Marcus SC. Understanding excess mortality in persons with mental illness: 17-year follow up of a nationally representative US survey. Med Care. 2011; 49:599–604.
39. Hayes JF, Marston L, Walters K, King MB, Osborn DPJ. Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000-2014. Br J Psychiatry. 2017; 211:175–181.
Article
40. Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care. 2009; 32:1037–1042.
Article
41. Mackin P, Bishop DR, Watkinson HM. A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients. BMC Psychiatry. 2007; 7:28.
Article
42. Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006; 86:15–22.
Article
43. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005; 19:Suppl 1. 1–93.
44. Cradock-O'Leary J, Young AS, Yano EM, Wang M, Lee ML. Use of general medical services by VA patients with psychiatric disorders. Psychiatr Serv. 2002; 53:874–878.
45. Druss BG, Bradford WD, Rosenheck RA, Radford MJ, Krumholz HM. Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry. 2001; 58:565–572.
Article
46. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH. From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A. 2007; 104:3456–3459.
Article
47. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003; 28:519–526.
Article
48. Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017; 13:757–777.
Article
49. Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med. 2011; 17:97–107.
Article
50. Silvestre JS, Prous J. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol. 2005; 27:289–304.
Article
51. Scaini G, Quevedo J, Velligan D, Roberts DL, Raventos H, Walss-Bass C. Second generation antipsychotic-induced mitochondrial alterations: implications for increased risk of metabolic syndrome in patients with schizophrenia. Eur Neuropsychopharmacol. 2018; 28:369–380.
Article
52. Abdel-Wahab BA, Metwally ME. Clozapine-induced cardiotoxicity: role of oxidative stress, tumour necrosis factor alpha and NF-κβ. Cardiovasc Toxicol. 2015; 15:355–365.
Article
53. Stubbs B, Wang AK, Vancampfort D, Miller BJ. Are leptin levels increased among people with schizophrenia versus controls? A systematic review and comparative meta-analysis. Psychoneuroendocrinology. 2016; 63:144–154.
Article
54. Goetz RL, Miller BJ. Meta-analysis of ghrelin alterations in schizophrenia: effects of olanzapine. Schizophr Res . 2018; In press.
Article
55. Yevtushenko OO, Cooper SJ, O'Neill R, Doherty JK, Woodside JV, Reynolds GP. Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. Br J Psychiatry. 2008; 192:424–428.
Article
56. Suetani RJ, Siskind D, Reichhold H, Kisely S. Genetic variants impacting metabolic outcomes among people on clozapine: a systematic review and meta-analysis. Psychopharmacology (Berl). 2017; 234:2989–3008.
Article
57. Bai YM, Chen TT, Liou YJ, Hong CJ, Tsai SJ. Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics. Schizophr Res. 2011; 125:179–186.
Article
58. Peet M. Diet, diabetes and schizophrenia: review and hypothesis. Br J Psychiatry Suppl. 2004; 47:S102–S105.
Article
59. De Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005; 76:135–157.
Article
60. Tsuruga K, Sugawara N, Sato Y, Saito M, Furukori H, Nakagami T, et al. Dietary patterns and schizophrenia: a comparison with healthy controls. Neuropsychiatr Dis Treat. 2015; 11:1115–1120.
Article
61. Hasnain M, Vieweg WV, Fredrickson SK, Beatty-Brooks M, Fernandez A, Pandurangi AK. Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications. Prim Care Diabetes. 2009; 3:5–15.
Article
62. Baker RA, Pikalov A, Tran QV, Kremenets T, Arani RB, Doraiswamy PM. Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis. Psychopharmacol Bull. 2009; 42:11–31.
63. Duncan EJ, Woolson SL, Hamer RM, Dunlop BW. Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a veterans affairs population. Int Clin Psychopharmacol. 2009; 24:204–213.
Article
64. Sicras-Mainar A, Maurino J, Ruiz-Beato E, Navarro-Artieda R. Prevalence of metabolic syndrome according to the presence of negative symptoms in patients with schizophrenia. Neuropsychiatr Dis Treat. 2015; 11:51–57.
65. Hammerman A, Dreiher J, Klang SH, Munitz H, Cohen AD, Goldfracht M. Antipsychotics and diabetes: an age-related association. Ann Pharmacother. 2008; 42:1316–1322.
Article
66. Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry. 2008; 69:Suppl 4. 26–36.
67. Kumra S, Oberstar JV, Sikich L, Findling RL, McClellan JM, Vinogradov S, et al. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull. 2008; 34:60–71.
Article
68. Holt RI, Peveler RC. Obesity, serious mental illness and antipsychotic drugs. Diabetes Obes Metab. 2009; 11:665–679.
Article
69. Coccurello R, Moles A. Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol Ther. 2010; 127:210–251.
Article
70. Fernandez-Egea E, Bernardo M, Donner T, Conget I, Parellada E, Justicia A, et al. Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br J Psychiatry. 2009; 194:434–438.
Article
71. Ryan MC, Flanagan S, Kinsella U, Keeling F, Thakore JH. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci. 2004; 74:1999–2008.
Article
72. Sengupta S, Parrilla-Escobar MA, Klink R, Fathalli F, Ying Kin Ng, Stip E, et al. Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls. Schizophr Res. 2008; 102:329–336.
Article
73. Enez Darcin A, Yalcin Cavus S, Dilbaz N, Kaya H, Dogan E. Metabolic syndrome in drug-naïve and drug-free patients with schizophrenia and in their siblings. Schizophr Res. 2015; 166:201–206.
Article
74. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry. 2003; 160:284–289.
Article
75. Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology. 2010; 35:1997–2004.
Article
76. Cohen D, De Hert M. Endogenic and iatrogenic diabetes mellitus in drug-naïve schizophrenia: the role of olanzapine and its place in the psychopharmacological treatment algorithm. Neuropsychopharmacology. 2011; 36:2368–2369.
Article
77. Cohn TA, Remington G, Zipursky RB, Azad A, Connolly P, Wolever TM. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can J Psychiatry. 2006; 51:382–386.
Article
78. Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH. Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabet Med. 2007; 24:481–485.
Article
79. Kirkpatrick B, Miller BJ, Garcia-Rizo C, Fernandez-Egea E, Bernardo M. Is abnormal glucose tolerance in antipsychotic-naive patients with nonaffective psychosis confounded by poor health habits? Schizophr Bull. 2012; 38:280–284.
Article
80. Thakore JH. Metabolic syndrome and schizophrenia. Br J Psychiatry. 2005; 186:455–456.
Article
81. Tschoner A, Engl J, Laimer M, Kaser S, Rettenbacher M, Fleischhacker WW, et al. Metabolic side effects of antipsychotic medication. Int J Clin Pract. 2007; 61:1356–1370.
Article
82. Graham KA, Perkins DO, Edwards LJ, Barrier RC, Lieberman JA, Harp JB. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry. 2005; 162:118–123.
Article
83. Wu RR, Zhao JP, Liu ZN, Zhai JG, Guo XF, Guo WB, et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl). 2006; 186:572–578.
Article
84. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 2003; 160:1396–1404.
Article
85. Sengupta SM, Klink R, Stip E, Baptista T, Malla A, Joober R. Weight gain and lipid metabolic abnormalities induced by olanzapine in first-episode, drug-naïve patients with psychotic disorders. Schizophr Res. 2005; 80:131–133.
Article
86. Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry Suppl. 2004; 47:S64–S66.
Article
87. Scheen AJ, De Hert MA. Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab. 2007; 33:169–175.
88. Hirsch L, Yang J, Bresee L, Jette N, Patten S, Pringsheim T. Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug Saf. 2017; 40:771–781.
Article
89. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry. 2006; 51:480–491.
Article
90. Ono S, Sugai T, Suzuki Y, Yamazaki M, Shimoda K, Mori T, et al. High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey. BMC Psychiatry. 2018; 18:180.
Article
91. Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K. First-v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2008; 192:406–411.
Article
92. Liao CH, Chang CS, Wei WC, Chang SN, Liao CC, Lane HY, et al. Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: a population-based study. Schizophr Res. 2011; 126:110–116.
Article
93. Kessing LV, Thomsen AF, Mogensen UB, Andersen PK. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry. 2010; 197:266–271.
Article
94. Luckhoff H, Phahladira L, Scheffler F, Asmal L, Du Plessis S, Chiliza B, et al. Weight gain and metabolic change as predictors of symptom improvement in first-episode schizophrenia spectrum disorder patients treated over 12 months. Schizophr Res. 2018; In press.
95. Sharma E, Rao NP, Venkatasubramanian G. Association between antipsychotic-induced metabolic side-effects and clinical improve ment: a review on the evidence for “metabolic threshold. ” Asian J Psychiatr. 2014; 8:12–21.
Article
96. Kemp DE, Correll CU, Tohen M, Delbello MP, Ganocy SJ, Findling RL, et al. Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia. J Child Adolesc Psychopharmacol. 2013; 23:522–530.
Article
97. Grover S, Hazari N, Chakrabarti S, Avasthi A. Metabolic disturbances, side effect profile and effectiveness of clozapine in adolescents. Indian J Psychol Med. 2016; 38:224–233.
Article
98. Raben AT, Marshe VS, Chintoh A, Gorbovskaya I, Müller DJ, Hahn MK. The complex relationship between antipsychotic-induced weight gain and therapeutic benefits: a systematic review and implications for treatment. Front Neurosci. 2017; 11:741.
Article
99. De Hert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, Sinko S, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res. 2008; 101:295–303.
Article
100. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Möller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009; 24:412–424.
Article
101. Straker D, Correll CU, Kramer-Ginsberg E, Abdulhamid N, Koshy F, Rubens E, et al. Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry. 2005; 162:1217–1221.
Article
102. Tirupati S, Chua LE. Body mass index as a screening test for metabolic syndrome in schizophrenia and schizoaffective disorders. Australas Psychiatry. 2007; 15:470–473.
Article
103. American Diabetes Association. American Psychiatric Association. American Association of Clinical Endocrinologists. North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004; 27:596–601.
104. Cooper SJ, Reynolds GP. With expert co-authors (in alphabetical order). Barnes T, England E, Haddad PM, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol. 2016; 30:717–748.
Article
105. Gabriele JM, Dubbert PM, Reeves RR. Efficacy of behavioural interventions in managing atypical antipsychotic weight gain. Obes Rev. 2009; 10:442–455.
Article
106. Alvarez-Jiménez M, Hetrick SE, González-Blanch C, Gleeson JF, McGorry PD. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry. 2008; 193:101–107.
Article
107. Sugawara N, Sagae T, Yasui-Furukori N, Yamazaki M, Shimoda K, Mori T, et al. Effects of nutritional education on weight change and metabolic abnormalities among patients with schizophrenia in Japan: a randomized controlled trial. J Psychiatr Res. 2018; 97:77–83.
Article
108. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001; 285:2486–2497.
109. Lakka TA, Laaksonen DE. Physical activity in prevention and treatment of the metabolic syndrome. Appl Physiol Nutr Metab. 2007; 32:76–88.
Article
110. Gurusamy J, Gandhi S, Damodharan D, Ganesan V, Palaniappan M. Exercise, diet and educational interventions for metabolic syndrome in persons with schizophrenia: a systematic review. Asian J Psychiatr. 2018; 36:73–85.
Article
111. Hermes E, Nasrallah H, Davis V, Meyer J, McEvoy J, Goff D, et al. The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophr Res. 2011; 128:166–170.
Article
112. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006; 163:611–622.
Article
113. Weiden PJ, Newcomer JW, Loebel AD, Yang R, Lebovitz HE. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology. 2008; 33:985–994.
Article
114. Zheng W, Li XB, Tang YL, Xiang YQ, Wang CY, De Leon J. Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol. 2015; 35:499–509.
Article
115. Ellul P, Delorme R, Cortese S. Metformin for weight gain associated with second-generation antipsychotics in children and adolescents: a systematic review and meta-analysis. CNS Drugs. 2018; 32:1103–1112.
Article
116. Siskind DJ, Leung J, Russell AW, Wysoczanski D, Kisely S. Metformin for clozapine associated obesity: a systematic review and meta-analysis. PLoS One. 2016; 11:e0156208.
Article
117. Fabrazzo M, La Pia S, Monteleone P, Mennella R, Esposito G, Pinto A, et al. Fluvoxamine increases plasma and urinary levels of clozapine and its major metabolites in a time- and dose-dependent manner. J Clin Psychopharmacol. 2000; 20:708–710.
Article
118. Lu ML, Chen TT, Kuo PH, Hsu CC, Chen CH. Effects of adjunctive fluvoxamine on metabolic parameters and psychopathology in clozapine-treated patients with schizophrenia: a 12-week, randomized, double-blind, placebo-controlled study. Schizophr Res. 2018; 193:126–133.
Article
119. Lu ML, Lane HY, Lin SK, Chen KP, Chang WH. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry. 2004; 65:766–771.
Article
120. Porfirio MC, Gomes de, Stornelli M, Giovinazzo S, Purper-Ouakil D, Masi G. Can melatonin prevent or improve metabolic side effects during antipsychotic treatments? Neuropsychiatr Dis Treat. 2017; 13:2167–2174.
Article
121. Agahi M, Akasheh N, Ahmadvand A, Akbari H, Izadpanah F. Effect of melatonin in reducing second-generation antipsychotic metabolic effects: a double blind controlled clinical trial. Diabetes Metab Syndr. 2018; 12:9–15.
Article
122. Romo-Nava F, Alvarez-Icaza González D, Fresán-Orellana , Saracco Alvarez R, Becerra-Palars C, Moreno J, et al. Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial. Bipolar Disord. 2014; 16:410–421.
Article
123. Koziróg M, Poliwczak AR, Duchnowicz P, Koter-Michalak M, Sikora J, Broncel M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J Pineal Res. 2011; 50:261–266.
Article
124. Lee SY, Park HS, Kim SM, Kwon HS, Kim DY, Kim DJ, et al. Cut-off points of waist circumference for defining abdominal obesity in the Korean population. Korean J Obes. 2006; 15:1–9.
125. Sugawara N, Yasui-Furukori N, Sato Y, Umeda T, Kishida I, Yamoshita H, et al. Prevalence of metabolic syndrome among patients with schizophrenia in Japan. Schizophr Res. 2010; 123:244–250.
Article
126. Huang MC, Lu ML, Tsai CJ, Chen PY, Chiu CC, Jian DL, et al. Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand. 2009; 120:274–280.
Article
127. Korean Society for Schizophrenia Research. Guideline for cardiovascular and metabolic syndrome. Seoul: Korean Society for Schizophrenia Research;2008.
Full Text Links
  • JKNA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr